Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETOUR: Safety and feasibility of immuno-OCT
2023-506395-27-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Barrett's esophagus, colon cancer and gastrointestinal intraepithelial neoplasia (GIN), sponsored by University Medical Center Groningen. Primary endpoints: Safety evaluation of immuno-OCT imaging and Feasibility of in vivo immuno-OCT imaging. Planned start Jan 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
Barrett's esophaguscolon cancergastrointestinal intraepithelial neoplasia (GIN)
Beyond the preview
Go deeper on 2023-506395-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506395-27-00.